- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Criteria for Discontinuing Treatment With an Amyloid-Targeting Therapy
Panelists discuss how treatment continuation decisions for amyloid-targeting therapies involve comprehensive assessment of multiple factors including cognitive and functional changes measured through standardized tools, occurrence and severity of adverse events, treatment adherence capabilities, impact on patient/caregiver quality of life, disease progression rate, emerging safety signals, and ongoing dialogue about evolving treatment goals and expectations.
EP: 1.Strategies for Enhancing Early Diagnosis and Implementation of Disease-Modifying Therapies in Alzheimer Disease
EP: 2.Advancing Early Alzheimer Diagnosis: Best Practices for Timely Screening and Detection
EP: 3.Care Pathways for Nonspecialist Providers When Evaluating Patients With Potential Mild Cognitive Impairment
EP: 4.Empowering Nonspecialist Providers and Addressing Gaps in Dementia Care: How Tools and Biomarkers Can Help
EP: 5.Factors to Evaluate When Selecting a Combination of Screening Assessments and Tests for Detecting Alzheimer Disease
EP: 6.From Time Constraints to Reimbursement: Addressing Key Hurdles in Cognitive Screening for Alzheimer Disease
EP: 7.Expanding Access to Alzheimer Disease Care: Leveraging Referral Networks and Telemedicine for Patients in Underserved Areas
EP: 8.Amyloid-Targeting Therapies in Alzheimer Disease: Mechanisms of Action, Efficacy, and Safety Considerations
EP: 9.Real-World Implications of Changes in CDR-SB Score in Patients Receiving Amyloid-Targeting Therapy
EP: 10.Patient Selection for Amyloid-Targeting Therapies: Key Characteristics and Considerations
EP: 11.Understanding the Hesitancy to Prescribe Amyloid-Targeting Therapies for Patients With Alzheimer Disease
EP: 12.Navigating the Risk-Benefit Conversation: Discussing Amyloid-Targeting Therapies With Patients and Caregivers
EP: 13.Criteria for Discontinuing Treatment With an Amyloid-Targeting Therapy
EP: 14.Strategies for Clinicians When Developing Protocols for Managing ARIA
EP: 15.Key Barriers in Managing Patients With Mild Cognitive Impairment Using Amyloid-Targeting Therapies
EP: 16.Access to Diagnostic Tests and Coverage for Amyloid-Targeting Therapies: Payer Considerations
EP: 17.Addressing Concerns About the Financial Impact of Amyloid-Targeting Therapies
EP: 18.Final Thoughts Alzheimer Disease Care
Video content above is prompted by the following:
- How do you decide whether to continue or discontinue treatment with an amyloid-targeting therapy?
Lack of CD20 Expression Worsens Outcomes for Bispecifics in R/R DLBCL
July 16th 2025Real-world analysis reveals that undetectable CD20 expression worsens outcomes for patients treated with epcoritamab and glofitamab bispecific antibodies for their diffuse large B-cell lymphoma (DLBCL).
Read More
